Ligand Pharmaceuticals Incorporated (LGND) Stock Price & How to Invest
Last updated November 2026
Short answer
Ligand Pharmaceuticals is a biopharmaceutical royalty aggregator, not a drug developer: it buys and licenses rights to a slice of other companies' drug sales, so the roughly ~20x trailing-sales multiple is priced against a stream of near-zero-cost royalty income rather than a product P&L. Owning LGND means underwriting the durability of a portfolio that now exceeds ~200 royalty positions and management's discipline in buying the next ones. As of October 16, 2026 the shares closed near $294.72, up about 55% year to date, for a market value of roughly ~$5.9B.
LGND stock price
As of 2026-11-16, Ligand Pharmaceuticals Incorporated (LGND) last closed at $301.71, up 49.8% over the past year. Over the past 52 weeks it has traded between $181.65 and $322.75.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Ligand Pharmaceuticals Incorporated's investor relations page. Walnut is informational, not investment advice.
LGND key stats
At $301.71 on November 16, 2026, Ligand Pharmaceuticals Incorporated (LGND) has a market cap of $6.0B and a P/E of 121.2 on trailing earnings (25.4 on forward earnings).
- Market cap
- $6.0B
- P/E (trailing)
- 121.2
- P/E (forward)
- 25.4
- EPS (trailing 12 months)
- $2.49
- Price to book
- 6.3
- Beta
- 1.03
Market cap, P/E and yield are measured at the $301.71 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Ligand Pharmaceuticals Incorporated (LGND)?
The last two weeks for Ligand Pharmaceuticals Incorporated, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- LGND closed at $301.71 on November 16, 2026, down 4.0% over the past five trading days (from $314.15).
- On November 5, 2026, Citigroup raised its target to $402.00 from $397.00 (Buy).
Ligand Pharmaceuticals Incorporated filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Ligand Pharmaceuticals Incorporated (LGND) latest quarter
Ligand reported revenue of $78.7 million for Q3 2026, down 32% from a year earlier (Ligand, Oct 29, 2026).
Source: Ligand Q3 2026 results, Oct 29, 2026. Full earnings breakdown
What does Ligand Pharmaceuticals Incorporated (LGND) do?
Ligand Pharmaceuticals earns money three ways, and only one of them looks like a normal drug company. Royalties on partnered medicines were ~$48.0M of the ~$63.7M reported in the June 2026 quarter, split between rights carried as intangible royalty assets (Filspari at ~$13.6M, Kyprolis ~$7.0M, Ohtuvayre ~$4.1M, Rylaze ~$3.2M, plus Capvaxive, Vaxneuvance and teriparatide) and financial royalty assets accounted for more like loans (Qarziba ~$6.2M, an Ohtuvayre inventors stream ~$3.3M). Captisol, a modified cyclodextrin that makes poorly soluble injectable drugs formulable and sits inside products such as Amgen's Kyprolis and Baxter's Nexterone, added ~$8.0M of material sales. Contract revenue and milestone income supplied the remaining ~$7.7M. Ligand runs no salesforce and no manufacturing plant for the drugs it collects on, which is the whole point of the structure.
That structure explains the multiple. A ~$5.9B market value on ~$291M of trailing revenue is about ~20x sales, a number that would be indefensible for a product company and is merely expensive for a royalty book where revenue arrives with almost no cost of goods attached. Trailing GAAP net income of ~$197M puts the trailing P/E near ~31x as of October 16, 2026 (about ~25x on 2027 consensus EPS of ~$11.95), and full-year 2026 guidance calls for revenue of ~$270M to ~$310M, royalties of ~$225M to ~$250M, and adjusted earnings of ~$9.00 to ~$9.50 per share. On July 14, 2026 Ligand closed a ~$739M all-cash acquisition of XOMA Royalty (each share took ~$39.00 plus a contingent value right tied to litigation proceeds), more than doubling the portfolio and adding commercial names including Vabysmo, Ojemda and Miplyffa. The debate is straightforward: royalty streams are contractual and finite, so the case rests on management replacing the declining ones faster than they run off. The shares closed near $294.72 on October 16, 2026, up about 55% year to date and about 63% over one year, and the September-quarter report on October 29 will be the first to show XOMA's contribution.
What's driving Ligand Pharmaceuticals Incorporated (LGND)?
1. The royalty line is compounding, not just holding
June-quarter royalties rose ~32% year over year to ~$48.0M, and the growth came from launches rather than price. Filspari royalties roughly doubled to ~$13.6M as Travere reported U.S. net sales near ~$141M, up ~96%, while the two Ohtuvayre-linked streams together contributed ~$7.4M against quarterly product sales of about ~$204M. Zelsuvmi and other newer launches sit in the smaller lines and have not yet reached scale.
2. XOMA Royalty more than doubled the portfolio
The ~$739M cash deal that closed in July 2026 took Ligand past ~200 royalty assets and brought in seven commercial products, ~14 late-stage programs and more than ~100 earlier-stage positions. Management guides the addition to contribute about ~$0.50 of adjusted EPS in the back half of 2026 and roughly ~$1.50 in 2027, with around ~$2.3B of gross milestone opportunity attached. It was funded from cash raised through a ~$700M convertible note carrying a ~0% coupon. Consensus for 2027 points the same way: analysts expect revenue near ~$381M and EPS near ~$11.95, up about 28% from the ~$9.31 expected for 2026.
3. Royalty economics convert revenue into cash
Operating cash flow was ~$72.7M in the first half of 2026 against ~-$9.6M a year earlier, and management expects more than ~$200M for the full year and roughly ~$300M in 2027. Cash and short-term investments stood at ~$1.36B on June 30 before the XOMA payment cleared. That balance, plus the zero-coupon financing, is what funds the next acquisitions.
4. Milestones and readouts are the unpriced option
Ligand has flagged up to ~7 registrational readouts across its partnered pipeline within about ~18 months. Palvella's QTORIN rapamycin carries an expected FDA decision in the first half of 2027, lasofoxifene has Phase 3 data due in the second half of 2027, and several Takeda programs including mezagitamab, osavampator and volixibat sit behind them. None of these require Ligand to spend development dollars, which is why they read as options rather than obligations.
What are the risks to Ligand Pharmaceuticals Incorporated (LGND)?
Ligand controls none of the products it earns from, so a partner's pricing decision, launch stumble or patent loss lands straight in royalty revenue with no operational lever to pull. Concentration is real and getting more so: Filspari alone was roughly ~28% of June-quarter royalties, while Kyprolis, Vaxneuvance and teriparatide all shrank year over year and Captisol material sales fell to ~$16.6M in the first half from ~$21.7M a year earlier. Reported earnings are noisy because mark-to-market swings on equity holdings flow through the income statement, which is how the March 2026 quarter produced a net loss despite positive operating income. About ~$1.16B of convertible notes now sits against a book of contractual but finite cash flows, and conversion pushes the share count above the ~21.8M diluted figure already used in the latest quarter. Ligand is separately in litigation with Viking Therapeutics over its termination of the TR-Beta license, and three complaints filed by tribal plaintiffs in 2019 name it within the opioid MDL in the Northern District of Ohio, where the company states no individualized allegations have been advanced against it. Expectations are also higher than they were: after a roughly 55% rise in 2026 the stock trades near ~31x trailing and ~25x forward earnings, and consensus for the September quarter (reported October 29, 2026) calls for ~$2.31 of adjusted EPS on ~$78M of revenue, so a soft first quarter of XOMA contribution could weigh on the shares.
What is the Ligand Pharmaceuticals Incorporated (LGND) forecast?
11 analysts publish price targets on LGND, averaging $360.82 as of November 2026, or +19.6% against the $301.71 share price on November 16, 2026. The published targets run from $335.00 to $406.00, a narrow spread, and the ratings split 11 buy, 0 hold, 0 sell. Over the last six months there have been 9 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full LGND forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is LGND a buy or a sell?
We give no verdict on Ligand Pharmaceuticals Incorporated. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. The royalty line is compounding, not just holding. June-quarter royalties rose ~32% year over year to ~$48.0M, and the growth came from launches rather than price. The most optimistic published target, $406.00, assumes this works close to its best case.
The case against. Ligand controls none of the products it earns from, so a partner's pricing decision, launch stumble or patent loss lands straight in royalty revenue with no operational lever to pull. The most pessimistic target, $335.00, is roughly what LGND is worth if this bites instead.
Read the full bull and bear case on LGND, including what would have to change to break either one. Walnut is not an investment adviser.
Has Ligand Pharmaceuticals Incorporated (LGND) split its stock?
Yes. Ligand Pharmaceuticals Incorporated (LGND) has had one share split in the last 10 years:
- 1603:1000 on November 2, 2022, so every share held became 1.603 shares.
A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of LGND the day before the 1603:1000 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.
Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.
How is Ligand Pharmaceuticals Incorporated (LGND) valued?
Market cap, P/E and dividend yield at today's price are in the LGND key stats above. The business figures below come from Ligand Pharmaceuticals Incorporated's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$291M (Q2 2026 +34% YoY)
- Royalty revenue (Q2 2026): ~$48.0M, up ~32% year over year
- Net income (TTM): ~$197M, about ~$9.49 per share
- FY2026 guidance: revenue ~$270M to ~$310M, adjusted EPS ~$9.00 to ~$9.50
- Balance sheet (June 30, 2026): ~$1.36B cash and short-term investments, ~$1.16B convertible notes, before ~$739M paid for XOMA in July
As of October 2026: A sales multiple is close to meaningless for a royalty book, because royalty revenue carries essentially no cost of goods and the expense base is an office of dealmakers rather than a commercial organisation. Measured against guided 2026 adjusted earnings of ~$9.00 to ~$9.50, the stock sits near ~31x, falling to about ~25x on 2027 consensus of ~$11.95, and management points to operating cash flow above ~$200M this year and around ~$300M next. What that price embeds, after a ~55% gain in 2026 and with analysts' mean target near ~$344, is an assumption that fresh royalty purchases keep arriving at accretive terms.
Who competes with Ligand Pharmaceuticals Incorporated (LGND)?
Royalty buyers
Royalty Pharma is far larger and bids on many of the same late-stage streams, alongside DRI Healthcare Trust, HealthCare Royalty, Blackstone Life Sciences and Sagard Healthcare. XOMA Royalty sat in this group until Ligand bought it in July 2026. Competition here shows up as the price paid per dollar of future royalty, not as customers lost, so a crowded market quietly compresses returns rather than revenue.
Other ways a biotech can raise money
A company that needs capital can issue equity, take venture debt or structured credit, or hand rights to a large pharma partner outright. When biotech equity windows are open and rates are friendly, fewer companies choose to sell a royalty, and the supply of deals Ligand can bid on thins out.
Formulation and solubilization suppliers
Captisol competes with Roquette's cyclodextrin lines, Ashland, Evonik and various CDMO formulation platforms, plus generic sulfobutylether beta-cyclodextrin producers as the underlying patents age. This is the one part of Ligand that behaves like a normal industrial supplier, with real cost of goods and real customer switching risk.
What stocks are similar to Ligand Pharmaceuticals Incorporated (LGND)?
Other names that sit close to LGND: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Ligand Pharmaceuticals Incorporated (LGND)
There are three common ways to get LGND exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so LGND sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where LGND fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Ligand Pharmaceuticals Incorporated (LGND)
LGND trades as a compounding royalty book rather than a pharma company, and the outcome turns on whether newly purchased streams keep outrunning the older ones that are already fading. The market has rewarded the strategy so far in 2026, with the stock up about 55% year to date, so the third-quarter report on October 29, the first to include XOMA, carries extra weight.
More on Ligand Pharmaceuticals Incorporated (LGND)
Whether LGND is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is LGND a buy or a sell?, and where the stock could go from here in the LGND stock forecast.
For income investors, whether LGND pays a dividend and how the payout looks is covered in does LGND pay a dividend? And to weigh LGND against a peer, read the full side-by-side comparisons: LGND vs RPRX and LGND vs DRI.
Wondering how LGND fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Ligand Pharmaceuticals Incorporated
Ask Walnut's AI anything about LGND and see how it fits what you own.
FAQ
What does Ligand Pharmaceuticals actually do?
+
It acquires and licenses royalty interests in medicines developed and sold by other companies, then collects a percentage of those sales. It also sells Captisol, a formulation ingredient used to make certain injectable drugs soluble and stable. Ligand does not run its own commercial drug business.
How does Ligand make money without selling drugs?
+
Partners such as Travere, Merck, Amgen and Jazz sell the products, report net sales, and pay Ligand a contracted royalty rate. Some positions are structured as purchased rights and reported as intangible royalty assets, while others are financed deals reported as financial royalty assets closer to loan accounting. Milestone payments and Captisol material sales fill out the rest.
Why does LGND trade at roughly 20 times sales?
+
Because royalty revenue arrives with almost no cost attached. A ~$1 of royalty converts to something close to ~$1 of gross profit, whereas a product company keeps a fraction after manufacturing and selling costs. On guided 2026 adjusted earnings of ~$9.00 to ~$9.50 the multiple is closer to ~31x as of October 2026, and about ~25x on 2027 consensus earnings, which are more useful comparisons.
Which royalty streams matter most?
+
Filspari for IgA nephropathy was the largest single contributor at ~$13.6M in the June 2026 quarter. Kyprolis (~$7.0M), Qarziba (~$6.2M) and the two Ohtuvayre-linked streams (~$7.4M combined) follow, with Rylaze, Capvaxive, Vaxneuvance, teriparatide and newer launches such as Zelsuvmi below them. The XOMA deal added Vabysmo, Ojemda and Miplyffa to the list.
What is Captisol and how much does it earn?
+
Captisol is a chemically modified cyclodextrin that improves the solubility and stability of drugs that would otherwise be difficult to inject. Material sales were ~$8.0M in the June 2026 quarter, with full-year guidance of ~$35M to ~$40M. Revenue has been drifting down since the COVID-era peak tied to remdesivir volumes.
What did the XOMA Royalty acquisition add?
+
Ligand paid ~$739M in cash, or ~$39.00 per XOMA share plus a contingent value right tied to a share of certain litigation proceeds, and closed on July 14, 2026. The deal took the combined portfolio past ~200 royalty assets and added seven commercial products and roughly ~14 late-stage programs. Management guides it to add about ~$0.50 of adjusted EPS in 2026 and ~$1.50 in 2027.
Does Ligand pay a dividend?
+
No. Cash generated by the royalty portfolio is retained and redeployed into new royalty purchases, and the company has also used proceeds from its convertible offerings to repurchase modest amounts of stock. Returns to shareholders have come through the share price rather than income.
What are the main risks in the LGND story?
+
Partner dependence is the structural one, since Ligand cannot influence how a licensee prices, launches or defends a product. Revenue concentration in Filspari, the run-off of older streams such as Kyprolis and Vaxneuvance, a declining Captisol line, ~$1.16B of convertible debt and mark-to-market volatility in reported earnings are the specific ones. There is also live litigation with Viking Therapeutics over a terminated license.
How did Ligand do in its latest quarter?
+
In the June 2026 quarter Ligand reported revenue of ~$63.7M, up ~34% year over year, with royalties of ~$48.0M and GAAP net income of ~$48.5M. Adjusted EPS of ~$2.37 beat the ~$1.95 consensus, after a narrow miss in the March quarter (~$1.63 against ~$1.80). September-quarter results are scheduled for October 29, 2026, with consensus near ~$2.31 of EPS on ~$78M of revenue.
How has LGND stock performed in 2026?
+
Strongly. As of the October 16, 2026 close near $294.72, LGND was up about 55% year to date and about 63% over one year, inside a 52-week range of roughly ~$176 to ~$327. It has been roughly flat over the past three months (about -3.5%) as the XOMA acquisition closed and investors waited for the first combined results.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Ligand Pharmaceuticals Incorporated's investor relations page or your broker before making investment decisions.